Combination of Radiotherapy and Immunotherapy for Unresectable Stage III Non-small Cell Lung Cancer: Clinical Progress Advances and Future Directions.
Stage III non-small cell lung cancer (NSCLC) accounts for approximately 30% of newly diagnosed NSCLC cases, and the vast majority of these patients present with unresectable disease. Its unresectable nature makes definitive chemoradiotherapy the cornerstone of treatment. In recent years, with immune...
| Publicado en: | Chinese Journal of Lung Cancer Vol. 28; no. 11; pp. 866 - 875 |
|---|---|
| Autores principales: | , , , |
| Formato: | review tables/charts Journal Article |
| Publicado: |
Chinese Journal of Lung Cancer
Nov2025
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=191474576&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 191474576 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 10093419 9014 jtl: Chinese Journal of Lung Cancer issn: 10093419 maglogo: N pubinfo: dt: Nov2025 vid: 28 iid: 11 pid: 54191 pub: Chinese Journal of Lung Cancer artinfo: ui: 191474576 191474576 191474576 10.3779/j.issn.1009-3419.2025.102.42 191474576 ppf: 866 ppct: 9 formats: fmt: @attributes: type: P tig: atl: Combination of Radiotherapy and Immunotherapy for Unresectable Stage III Non-small Cell Lung Cancer: Clinical Progress Advances and Future Directions. aug: au: TAN, Zuoyuan ZHONG, Yuling WANG, Jingyi WU, Lin affil: Graduate Collaborative Training Base of Hunan Cancer Hospital, University of South China, Hengyang Medical School, Hengyang 421001, China sug: subj: Carcinoma, Non-Small-Cell Lung Radiotherapy Neoplasm Staging Immunotherapy Combined Modality Therapy Radiotherapy Immune Checkpoint Inhibitors Tumor Markers, Biological Programmed Cell Death Ligand 1 DNA RNA ab: Stage III non-small cell lung cancer (NSCLC) accounts for approximately 30% of newly diagnosed NSCLC cases, and the vast majority of these patients present with unresectable disease. Its unresectable nature makes definitive chemoradiotherapy the cornerstone of treatment. In recent years, with immune checkpoint inhibitors (ICIs) becoming a major research focus in lung cancer, increasing evidence demonstrates that the combination of radiotherapy and immunotherapy (iRT) can significantly enhance antitumor efficacy through synergistic mechanisms. The groundbreaking results of the landmark PACIFIC trial further established consolidation immunotherapy following concurrent chemoradiotherapy as the standard of care. However, controversies persist regarding optimal radiotherapy strategies, timing of immune intervention, management of adverse reactions, and exploration of biomarkers. This review aims to systematically elucidate the synergistic mechanisms of iRT, summarize clinical trial advances under different iRT treatment modalities (concurrent, consolidation and induction), and provide an in-depth analysis of key issues in current clinical practice along with future research directions. pubtype: Academic Journal doctype: review tables/charts Journal Article ougenre: Article language: Chinese refInfo: holdings: @attributes: islocal: N |
|---|